Metagenomics Market Size
| Study Period | 2018 - 2028 |
| Base Year For Estimation | 2021 |
| Forecast Data Period | 2024 - 2028 |
| CAGR | 12.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Metagenomics Market Analysis
The metagenomics market is expected to register a CAGR of 12.6% over the forecast period, 2022-2027.
The COVID-19 pandemic is expected to have shifted the focus to the growth of the metagenomics market. Metagenomics is widely used in analyzing the interactions between the microbiome and various pathological interventions associated with COVID-19 infection. Metagenomic next-generation sequencing (mNGS) is one of the advanced techniques in detecting SARS-CoV-2 from nasopharyngeal (NP) swabs and also provides information on the composition of the microbiome in the upper respiratory tract and aids in analyzing its relationship to coinfections or the presence of other organisms that may impact SARS-CoV-2 disease progression and prognosis. According to the research article titled' Metagenomics: preventing future pandemics' published in Future Science, 2021, pandemic risk calculations make use of technologies such as metagenomics to trace the molecular changes in pathogens during their emergence globally, which could assist in the prediction of hotspots of emergence, populations at risk, and the pathogens under genetic evolution. Thus, given the aforementioned factors, the COVID-19 pandemic is expected to have a significant impact on the metagenomics market.
Increasing awareness about metagenomics is attributed to the increasing Research and development expenditure, declining expenses of sequencing, and technological advancements. Besides, the growing interest of researchers in the field of metatranscriptomics, metabolomics, and metaproteomic and investments in bioinformatics to promote metagenomics and microbiome profiling are also some of the factors propelling the growth of the market. for instace, in January 2022 SeqOne company raised EUR 20 Million in a Series A round as growing investments reach startups delivering the next generations of genomics and bioinformatics. Moreover, as DNA sequencing is highly associated with metagenomics, the technological advancement in the field of DNA sequencing results in several advantages compared to conventional methods. The features of accuracy, reducing the number of pre-sequencing, and reliability on sequencing have added to increased dependence on the technology in metagenomics. Hence, the advancements in DNA sequencing are expected to propel the market for metagenomics in the coming years. Furthermore, rising concerns related to viral diseases such as virus-induced diarrhea, influenza, hepatitis B, and HIV/AIDS and a growing number of genes being identified have led to the development of novel metagenome study products. According to United Nations AIDS, 2022, 37.7 million people globally were living with HIV. 79.3 million people have become infected with HIV since the start of the epidemic. New HIV infections have been reduced by 52%. And around 1.5 million people were newly infected with HIV.
Thus the above mentioned factors are expected to drive the growth of the market during the forecast period. However, the high cost of overall metagenomics may hamper the market to a certain extent.
Metagenomics Market Trends
This section covers the major market trends shaping the Metagenomics Market according to our research experts:
Metagenomics Application in Human Health is Expected to Witness Healthy Growth Over the Forecast Period
Metagenomics in human health is anticipated to show significant growth in the forecast period due to growing demand among researchers to study the relationship between microbes and human diseases. The shotgun characterization of total DNA and marker genes is used mainly to analyze the community structure of the human microbiome, which is the genetic material of the microbes associated with humans. According to the article titled ' Metagenomics Study Reveals changes in gut microbiota in Centenarians: A cohort study of Hainan centenarians' published in the American Society of Microbiology, July 2020, the metagenomic changes of the human gut microbiota studied and described, that occur with aging, up to extreme longevity, by characterizing the microbiome of semisupercentenarians, i.e., the population aged above 105 years, and thus aids in the development and support of new homeostasis. Additionally, metagenomic next-generation sequencing (mNGS) of RNA and DNA extracted from cerebrospinal fluid and brain tissue offers a potential strategy for diagnosing neurological infections. Also, as per the research article titled ' Addressing learning needs on the use of metagenomics in antimicrobial resistance surveillance' published in Frontiers in Public Health, February 2020, metagenomics-based surveillance helps in detecting the relation between pathogens and antimicrobial resistance. Metagenomics has been extensively used in the identification of the microbiome associated with the onset of various cancers, such as colorectal cancers. Hence, the high incidence of cancers globally surges the research studies to evaluate the microbiome associated with cancer and the possible diagnostic/treatment options, which is expected to drive the studied segment.
Also, the COVID-19 pandemic has shed light on the application of metagenomics in the detection and analysis of the SARS-CoV2 virus. Metagenomics plays a vital role in determining and analyzing the microbiome associated with upper respiratory tract infection (URTI), chronic obstructive pulmonary disease (COPD), and COVID-19 disease, which is of great importance during the current pandemic era. An article titled ' Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID-19 respiratory diseases' published in June 2021, revealed the presence of 30 functional gene groups/classes associated with resistance to antibiotics and toxic compounds (RATC) in both COVID-19 and non-COVID-19 microbiomes. Furthermore, a predominant higher abundance of cobalt-zinc-cadmium resistance (CZCR) and multidrug resistance to efflux pumps (MREP) genes were detected in the COVID-19 metagenome. Thus, COVID-19 is expected to positively impact the studied market growth during the current pandemic.
Furthermore, the European Project MetaHIT (metagenomics of human intestinal tract) and the American Human Microbiome Project are some of the research programs working in the field of metagenomics. Moreover, rising investment in the human microbiome and the introduction of advanced sequencing technologies have been driving the metagenomics market over the forecast period.
North America is Expected to Hold a Significant Share of the Market Over the the Forecast Period
North America is expected to hold a significant market due to the presence of a large number of pharmaceutical and biotechnological companies working toward the establishment of novel and efficient metagenomic platforms, along with the increasing research and development expenditure by the key players. Also, the wide adoption of metagenomics diagnostic and an increasing number of next-generation sequencing (NGS)-based research and technological advancements are driving the studied market in the region.
The growing application of metagenomics in various COVID-19 studies is also expected to drive the studied market during the pandemic. According to the research article published in the American Society of Microbiology, 2020, China, the United States, and Europe had various levels of coinfection during COVID-19, within regions as well that ranged from as low as 2% to as high as 80%. Metagenomic-based next-generation sequencing (mNGS) has the ability to detect coinfections and determine other organisms that may impact patient outcomes.
The United States owns the largest share of the metagenomics market in the North American region. The rising geriatric population and the high incidence of chronic diseases are also expected to play a vital role in the growth of the studied market. According to the report by America's Health Rankingds in 2021, more than 54 million adults aged 65 and older live in United States. The number of older adults aged in 65 and older was projected to rise to an estimated 85.7 million of overall United States population. Thus, the elderly population is more prone to chronic diseases, which surges the demand for advanced diagnostics and treatment planning. Hence, the rapid adoption of novel sequencing technologies and rising awareness about next-generation sequencing (NGS) based on metagenomic research are also expected to fuel the market in this region.
Metagenomics Industry Overview
The metagenomics market is moderately competitive and consists of several major players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. include Illumina Inc., QIAGEN NV, Novogene Co. Ltd, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc., among others.
Metagenomics Market Leaders
Illumina, Inc
PerkinElmer Inc.
QIAGEN N.V.
F. Hoffmann-La Roche Ltd
Novogene Co., Ltd
*Disclaimer: Major Players sorted in no particular order
Metagenomics Market News
In January 2022 Metagenomi raised USD 175 million to advance the therapeutic pipeline and expand the gene editing platform.
In December 2021, Oriel Research launched a metagenomics pipeline for supporting the metagenomics analysis to allow full synergism between big data bioinformatics analytical tools and novel biological platforms, to deliver metagenomics discoveries to patients.
Metagenomics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Expenditure
4.2.2 Declining Expenses of Sequencing
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Overall Cost of Metagenomics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Sequencing and Data Analytics Services
5.1.2 Kits and Reagents
5.1.3 Other Products
5.2 By Technology
5.2.1 Sequencing Driven
5.2.2 Function Driven
5.3 By Application
5.3.1 Human Health
5.3.2 Environmental
5.3.3 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 QIAGEN NV
6.1.3 Novogene Co. Ltd
6.1.4 PerkinElmer Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Thermo Fisher Scientific
6.1.7 Promega Connections
6.1.8 Bio-Rad Laboratories Inc.
6.1.9 Merck KGaA
6.1.10 BGI Group
6.1.11 Eurofins Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Metagenomics Industry Segmentation
As per the scope, metagenomics deals with the study in which it acts as a molecular tool that uses sequencing technologies and bioinformatics tools to analyze DNA acquired from environmental samples. The Metagenomics Market is Segmented by Product (Sequencing and Data Analytics Services, Kits, and Reagents, and Other Products), Technology (Sequencing Driven and Function Driven), Application (Human Health, Environmental, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Product | |
| Sequencing and Data Analytics Services | |
| Kits and Reagents | |
| Other Products |
| By Technology | |
| Sequencing Driven | |
| Function Driven |
| By Application | |
| Human Health | |
| Environmental | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Metagenomics Market Research FAQs
What is the current Global Metagenomics Market size?
The Global Metagenomics Market is projected to register a CAGR of 12.6% during the forecast period (2023-2028).
Who are the key players in Global Metagenomics Market?
Illumina, Inc, PerkinElmer Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd and Novogene Co., Ltd are the major companies operating in the Global Metagenomics Market.
Which is the fastest growing region in Global Metagenomics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Global Metagenomics Market?
In 2023, the North America accounts for the largest market share in the Global Metagenomics Market.
Global Metagenomics Industry Report
Statistics for the 2023 Global Metagenomics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Metagenomics analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
